Press Releases
Dec 1, 2025
Funding to support development of Katana™ Thrombectomy System and NavIQ™ quantification software, enrollment completion of QUADRA-PE study and key regulatory milestones LOS GATOS, Calif., December 1, 2025 – Akura Medical, a Shifamed portfolio company focused on reshaping the landscape of venous thromboembolism (VTE) care, announced today it has secured a $53 million first close in Series
Nov 4, 2024
Akura Medical, a Shifamed portfolio company focused on reshaping the landscape of venous thromboembolism (VTE) care, announced today the US Food and Drug Administration has approved its Investigational Device Exemption (IDE) application to initiate the QUADRA-PE study (NCT06672510) evaluating the Katana™ Thrombectomy System in patients with acute pulmonary embolism (PE).
Oct 30, 2023
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the Late-Breaking Clinical Trials session at The VEINS conference, hosted at Wynn Las Vegas.
Oct 3, 2023
Akura Medical, a Shifamed portfolio company focused on a differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), announced today the closing of its $35M Series B financing. The funds will be used to apply for FDA 510(k) clearance for the Akura Mechanical Thrombectomy Platform, support clinical trials for additional indications, and scale manufacturing capabilities.
May 18, 2023
Just over a year ago, Murali Srivathsa joined Akura Medical as CEO, leaving his position as the head of global marketing for Abbott’s heart failure division. With 25 years of experience in commercial and marketing roles, including multiple exits in the cardiac space, Srivathsa believes that mechanical treatment of venous thromboembolism (VTE), which encompasses both PE and deep vein thrombosis (DVT), is on the cusp of strong growth.
May 10, 2023
Akura Medical, a Shifamed portfolio company focused on a differentiated approach delivering an effective solution to address the major challenges of venous thromboembolism (VTE), announced today it has initiated its first-in-human clinical study of the Akura Mechanical Thrombectomy Platform. The Akura platform is a low-profile solution designed to easily access and efficiently remove large volume, mixed morphology clots, and eliminate the guesswork around the procedure. The initial 5 cases were performed in the Republic of Georgia and marked the first use of mechanical thrombectomy for pulmonary embolism (PE) in the country.
Apr 19, 2022
Akura Medical, Inc., a Shifamed portfolio company, announced today that seasoned medtech executive, Murali Srivathsa, has joined as President and CEO. With over two decades of industry experience, Murali brings a wealth of medical device and senior leadership expertise. He joins as the team finalizes product development of its next-generation thrombectomy device.
Jan 10, 2022
Akura Medical, Inc., a Shifamed portfolio company, announced today the closing of its $25M Series A1 financing, which will be used to support the development of its next-generation thrombectomy device. The financing was led by Cormorant Asset Management, with participation from The Capital Partnership (TCP), PA MedTech VC Fund and Shifamed angel investors.
